Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events
Top Cited Papers
- 1 October 2009
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 361 (14), 1329-1338
- https://doi.org/10.1056/nejmoa0906431
Abstract
This trial was designed to determine whether cardiac-resynchronization therapy (CRT) with biventricular pacing would reduce the risk of death or heart-failure events in patients with mild cardiac symptoms, a reduced ejection fraction, and a wide QRS complex. During a 4.5-year period, we enrolled and followed 1820 patients with ischemic or nonischemic cardiomyopathy, an ejection fraction of 30% or less, a QRS duration of 130 msec or more, and New York Heart Association class I or II symptoms. Patients were randomly assigned in a 3:2 ratio to receive CRT plus an implantable cardioverter–defibrillator (ICD) (1089 patients) or an ICD alone (731 patients). The primary end point was death from any cause or a nonfatal heart-failure event (whichever came first). Heart-failure events were diagnosed by physicians who were aware of the treatment assignments, but they were adjudicated by a committee that was unaware of assignments. During an average follow-up of 2.4 years, the primary end point occurred in 187 of 1089 patients in the CRT–ICD group (17.2%) and 185 of 731 patients in the ICD-only group (25.3%) (hazard ratio in the CRT–ICD group, 0.66; 95% confidence interval [CI], 0.52 to 0.84; P=0.001). The benefit did not differ significantly between patients with ischemic cardiomyopathy and those with nonischemic cardiomyopathy. The superiority of CRT was driven by a 41% reduction in the risk of heart-failure events, a finding that was evident primarily in a prespecified subgroup of patients with a QRS duration of 150 msec or more. CRT was associated with a significant reduction in left ventricular volumes and improvement in the ejection fraction. There was no significant difference between the two groups in the overall risk of death, with a 3% annual mortality rate in each treatment group. Serious adverse events were infrequent in the two groups. CRT combined with ICD decreased the risk of heart-failure events in relatively asymptomatic patients with a low ejection fraction and wide QRS complex. (ClinicalTrials.gov number, NCT00180271.)Keywords
This publication has 17 references indexed in Scilit:
- ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm AbnormalitiesCirculation, 2008
- Variable Impact of Combining Fatal and Nonfatal End Points in Heart Failure TrialsCirculation, 2006
- Causes and Consequences of Heart Failure After Prophylactic Implantation of a Defibrillator in the Multicenter Automatic Defibrillator Implantation Trial IICirculation, 2006
- Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of CardiologyJournal of the American Society of Echocardiography, 2005
- Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT‐CRT): Design and Clinical ProtocolAnnals of Noninvasive Electrocardiology, 2005
- Percent right ventricular pacing predicts outcomes in the DAVID trialHeart Rhythm, 2005
- Sequential tests and estimators after overrunning based on maximum-likelihood orderingBiometrika, 2002
- Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection FractionThe New England Journal of Medicine, 2002
- Conflict-of-Interest Guidelines for a Multicenter Clinical Trial of Treatment after Coronary-Artery Bypass-Graft SurgeryThe New England Journal of Medicine, 1989